VivoSeq
Other

Intestinal Perforation

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Intestinal Perforation is an early-stage landscape with 1 program across 1 company. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Effect of Early Hydrocortisone on Risk of Gastrointestinal Perforations in Extremely Preterm Infants
Active, not recruiting·IImperial College London·N/A·NCT06515405·16,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)